NCT00130728

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 636 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	bevacizumab	intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
DRUG	erlotinib HCl	oral erlotinib HCl 150 mg/day orally
DRUG	placebo	intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle

Timeline

• Start date: 2005-06-08
• Primary completion: 2008-07-15
• Completion: 2019-12-23
• First posted: 2005-08-16
• Last updated: 2021-01-14
• Results posted: 2011-11-03

Locations

4 sites across 1 country: United States